Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe

Clinical Infectious Diseases

Volumn 56, Issue 3, 2013, Pages 430-446

  Ciaranello, Andrea L ^a   Perez, Freddy ^d,e   Engelsmann, Barbara ^f   Walensky, Rochelle P ^a,b,c   Mushavi, Angela ^g   Rusibamayila, Asinath ^b   Keatinge, Jo ^h   Park, Ji Eun ^b   Maruva, Matthews ^h   Cerda, Rodrigo ^a   Wood, Robin ⁱ   Dabis, Francois ^d   Freedberg, Kenneth A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e PAN AMERICAN HEALTH ORGANIZATION   (United States)

^f Organisation for Public Health Interventions and Development   (United States)

^g Ministry of Health and Child Welfare   (United States)

^h UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

cost effectiveness; HIV; mother to child transmission; pediatric HIV; PMTCT

Indexed keywords

CD4 ANTIGEN; NEVIRAPINE;

ADULT; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ZIMBABWE;

ANTI-HIV AGENTS; CHILD; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LIFE EXPECTANCY; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; WORLD HEALTH ORGANIZATION; YOUNG ADULT; ZIMBABWE;

EID: 84872343291     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis858     Document Type: Article

References (99)

1. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Available at: http://whqlibdoc.who.int/publications/2010/9789241599818-eng.pdf. Accessed 30 January 2012.
2. UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Available at: http://www.unaidsrstesa.org/sites/default/files/global-plan-elimina tion-hiv-children-en-1.pdf. Accessed 30 May 2012.
3. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Available at: http://www.who.int/hiv/PMTCT-update.pdf. Accessed 6 June 2012.
4. World Health Organization. Progress report 2011: global HIV/AIDS response: epidemic update and health sector progress towards universal access. Available at: http://www.who.int/hiv/pub/progress-report2011/en/index.html. Accessed 26 January 2012.
5. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report. Available at: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed 30 January 2012.
6. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24: F11-14.
7. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378:282-4.
8. Zimbabwe Ministry of Health. National HIV estimates. Harare: Zimbabwe Ministry of Health and Child Welfare, 2009.
9. Index Mundi. Zimbabwe birth rate. Available at: http://www. indexmundi.com/zimbabwe/birth-rate.html. Accessed 30 May 2012.
10. Ciaranello AL, Perez F, Maruva M, et al. WHO 2010 guidelines for prevention of mother-to-childHIVtransmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One 2011; 6:e20224.
11. Ciaranello A, Lockman S, Freedberg KA, et al. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a costeffectiveness analysis of the OCTANE trial. AIDS 2011; 25:479-92.
12. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med 2006; 355:1141-53.
13. Ciaranello A, Perez F, Engelsmann B, et al. Clinical and economic impact of scaling-up World Health Organization (WHO) 2010 PMTCT guidelines in Zimbabwe [abstract TuPE284]. In: Program and abstracts of the 6th International AIDS Society Conference on HIV pathogenesis, treatment and prevention. (Rome, Italy). Available at: http://pag.ias2011.org/Abstracts.aspx?AID=862. Accessed 22 February 2012.
14. Ciaranello AL, Perez F, Keatinge J, et al. What will it take to eliminate pediatric HIV? Reaching "virtual elimination" targets for prevention of mother-to-child HIV transmission (PMTCT) in Zimbabwe. PLoS Medicine 2012; 9:e1001156.
15. Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resourcelimited settings: a model-based analysis. PLoS Med 2010; 7:e1000382.
16. Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY. Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis 2009; 49:1784-92.
17. World Health Organization. WHO-CHOICE: cost-effectiveness thresholds. Available at: http://www.who.int/choice/costs/CER-thres holds/en/index.html. Accessed 30 January 2012.
18. World Bank. GDP per capita (current US$). Available at: http://worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 11 October 2012.
19. Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R. Costeffectiveness of antiretroviral therapy for prevention. Curr HIV Res 2011; 9:405-15.
20. Iliff P, Ntozini R, Nathoo K, Piwoz E, Moulton L, Humphrey J. Making a working clinical diagnosis of HIV infection in infants in Zimbabwe. Trop Med Int Health 2008; 13:1459-69.
21. Ministry of Health and Child Welfare Zimbabwe. Maternal and Perinatal Mortality Study 2007. Harare, Zimbabwe: Author, 2008.
22. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: recommendations for a public health approach (2010 version). Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/ index.html. Accessed 30 January 2012.
23. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents - recommendations for a public health approach (2010 version). Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed 30 January 2012.
24. Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIVfree survival. AIDS 2005; 19:699-708.
25. Lawn SD, Myer L, Orrell C, Bekker LG,Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-8.
26. UNAIDS Reference Group on Estimates MaP. Working paper on mother-to-child HIV transmission rates for use in Spectrum. Available at: http://www.epidem. org/Publications/MTCTratesworking paper.pdf. Accessed 8 June 2012.
27. William J. Clinton Foundation. Clinton Foundation HIV/AIDS Initiative (CHAI) antiretroviral price list, August 2009. Available at: http://www.clintonfoundation.org/files/chaiarvpricelistaugust2009english.pdf. Accessed 22 February 2012.
28. World Health Organization (WHO-CHOICE). Prices for hospitals and health centers. Available at: http://www.who.int/choice/en/. Accessed 30 January 2012.
29. World Health Organization. Global plan on elimination of new HIV infections among children and keeping their mothers alive. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/pcb/2011/12/ 20111215-Global%20Plan.pdf. Accessed 30 May 2012.
30. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-67.
31. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 2010; 53:405-11.
32. Toro PL, Katyal M, Carter RJ, et al. Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4 + cell count response and program retention. AIDS 2010; 24:515-24.
33. Cleary S, Chitha W, Jikwana S, Okorafor OA, Boulle A. Health Systems Trust: South African health review. Available at: http://www. healthlink.org.za/publications/682. Accessed 22 February 2012.
34. Dabis F, Stringer J. Debate: HAART should be used for PMTCT in all pregnant women (3rd International Workshop on HIV Pediatrics). Available at: http://regist2.virology-education.com/2011/3hiv ped/16-July.html; http://regist2.virology-education.com/supplement/supplement-2011-3.pdf. Accessed 22 February 2012.
35. National Institutes of Health: IMPAACT Trial Network. P1077: The PROMISE Study (Promoting Maternal and Infant Survival Everywhere). Synopsis, 2010. Available at: https://inpaactgroup.org/promise-featured-study. Accessed 8 November 2012.
36. Kesho Bora Study Group. Impact of triple-ARV prophylaxis during pregnancy and breastfeeding compared with short-ARV prophylaxis for MTCT prevention on maternal disease progression [abstract ThLBB105]. In: Programs and abstracts of XVII International AIDS Society (Vienna, Austria). Geneva, Switzerland: International AIDS Society, 2010.
37. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
38. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-9.
39. Walensky RP, Wood R, Fofana MO, et al. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 2011; 56:26-35.
40. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
41. Orlando S, Marazzi M, Mancinelli S, et al. Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi. J Acquir Immune Defic Syndr 2010; 55:631-4.
42. Shah M, Johns B, Abimiku A, Walker DG. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 2011; 25:1093-102.
43. Persaud D, Bedri A, Ziemniak C, et al. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retroviruses 2011; 27:823-9.
44. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
45. Johri M, Ako-Arrey D. The cost-effectiveness of preventing motherto- child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc 2011; 9:3.
46. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-8.
47. Carter RJ, Dugan K, El-Sadr WM, et al. CD4 + cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resourcelimited settings. J Acquir Immune Defic Syndr 2010; 55:404-10.
48. UNAIDS/UNICEF/WHO. Children and AIDS: fourth stocktaking report, actions and progress. Available at: http://www.unicef.org/publications/index-51902.html. Accessed 2 February 2012.
49. Ahoua L, Ayikoru H, Gnauck K, et al. Evaluation of a 5-year programme to prevent mother-to-child transmission of HIV infection in Northern Uganda. J Trop Pediatr 2010; 56:43-52.
50. Manzi M, Zachariah R, Teck R, et al. High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health 2005; 10:1242-50.
51. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS 2008; 22:1679-81.
52. Peltier CA, Ndayisaba GF, Lepage P, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23:2415-23.
53. Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health 2010; 15:825-32.
54. Kumwenda J, Mataya R, Kumwenda N, Kafulafula G, Li Q, Taha T. Coverage of highly active antiretroviral therapy (HAART) among postpartum women in Malawi (Abstract WEPDD106). In: Program and abstracts of 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town,South Africa). Geneva, Switzerland: International AIDS Society, 2009.
55. Chigwedere P, Seage GR, Lee TH, Essex M. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retroviruses 2008; 24:827-37.
56. Fawzi WW, Msamanga GI, Hunter D, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 2002; 16:1935-44.
57. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent motherto- child transmission of HIV-1 in West Africa. AIDS 2002; 16: 631-41.
58. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-86.
59. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Mwiya M, Thea DM.Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission. AIDS 2010; 24:1374-7; additional data at http://www.hivpresentation.com/index.cfm?vId=5BB28A44-423A-F6F7- C70DC6EC268CFF57&cID= 5C3B824B-423A-F6F7-C2E8CE9BBF9B2D92&show=slide. Accessed 3 October 2012.
60. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
61. Thistle P, Gottesman M, Pilon R, et al. A randomized control trial of an ultra-short zidovudine regimen in the prevention of perinatal HIV transmission in rural Zimbabwe. Cent Afr J Med 2004; 50:79-84.
62. Mofenson L, Taha T, Li Q, et al. Infant extended antiretroviral (ARV) prophylaxis is effective in preventing postnatal mother-to-child HIV transmission (MTCT) at all maternal CD4 counts [abstract TUPEC053]. In: Program and abstracts of 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Geneva, Switzerland: International AIDS Society, 2009.Available at: http://www.ias2009.org/pag/ Abstracts.aspx? AID=1251. Accessed 3 October 2012.
63. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-29.
64. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19:309-18.
65. Kesho Bora Study Group. Eighteen-month follow-up of HIV-1- infected mothers and their children enrolled in the Kesho Borastudy observational cohorts. J Acquir Immune Defic Syndr 2010; 54:533-41.
66. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-80.
67. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens inpregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-94.
68. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52:406-16.
69. Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007; 4:e257.
70. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV- 1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 1:159.
71. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794-805.
72. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15:379-87.
73. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998; 352:597-600.
74. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-81.
75. Vyankandondera J, Luchters S, Hassink E. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA-study) [abstract LB07). In: Program and abstracts of 2nd International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. (Paris, France). Geneva, Switzerland: International AIDS Society, 2003. Available at: http://www.iasociety.org/Default.aspx?pageId= 11&abstractId=11061. Accessed 26 June 2012.
76. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21(Suppl 4): S65-71.
77. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding - the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:e1001015.
78. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-43.
79. Crampin AC, Floyd S, Glynn JR, et al. The long-term impact of HIV and orphanhood on the mortality and physical well-being of children in rural Malawi. AIDS 2003; 17:389-97.
80. Nakiyingi JS, Bracher M, Whitworth JA, et al. Child survival in relation to mother's HIV infection and survival: evidence from a Ugandan cohort study. AIDS 2003; 17:1827-34.
81. Zaba B, Whitworth J, Marston M, et al. HIV and mortality of mothers and children: evidence from cohort studies in Uganda, Tanzania, and Malawi. Epidemiology 2005; 16:275-80.
82. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007; 26:519-26.
83. Marston M, Becquet R, Zaba B, et al. Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol 2011; 40:385-96.
84. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub- Saharan Africa. Lancet Infect Dis 2008; 8: 477-89.
85. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS 2004; 18:1905-13.
86. World Bank. World development indicators. Available at: http://data. worldbank.org/data-catalog/world-development-indicators. Accessed 30 January 2012.
87. United Nations. World population prospects: the 2008 revision. Available at: http://www.un.org/esa/population/publications/wpp2008/wpp2008-highlights. pdf. Accessed 30 January 2012.
88. Coetzee D, Hildrebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95.
89. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-509.
90. Stringer JS, McConnell MS, Kiarie J, et al. Effectiveness of nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose ofnevirapine: a multi-country, prospective cohort study. PLoS Med 2010; 7:e1000233.
91. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47.
92. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-72.
93. Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007-12.
94. Kombe G, Galaty D, Gadhia R, Decker C. Human and financial resource requirements for scaling up HIV/AIDS services in Ethiopia. Available at: http://www.healthsystems2020.org/content/resource/detail/1521. Accessed 22 February 2012.
95. Bratt JH, Torpey K, Kabaso M, Gondwe Y. Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. Trop Med Int Health 2011; 16:110-8.
96. Vander Plaetse B, Hlatiwayo G, Van Eygen L, Meessen B, Criel B. Costs and revenue of health care in a rural Zimbabwean district. Health Policy Plan 2005; 20:243-51.
97. Zar HJ, Workman L, le Roux SM, et al. A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. AIDS 2010; 24:2225-32.
98. Soderlund N, Zwi K, Kinghorn A. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ 1999; 318:1650-6.
99. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464-9.